Pfizer (PFE) Granted FDA Breakthrough Therapy Designation for 20-Valent Pneumococcal Conjugate Vaccine for Prevention of Invasive Disease and Pneumonia in Adults
September 20, 2018 8:05 AM
Pfizer Inc. (NYSE: PFE) announced today that its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) candidate, PF-06482077, received Breakthrough Therapy designation from ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)